Having trouble accessing articles? Reset your cache.

Plavix clopidogrel: Post-marketing study data

Researchers from McMaster University and colleagues reported data from a genotype analysis of patients with ACS or AF showing that Plavix reduced the rate of cardiovascular events vs. placebo, irrespective of cytochrome P450 2C19 (CYP2C19) loss-of-function carrier status. Specifically, analysis of 5,059 ACS patients from the Phase III CURE trial showed that Plavix significantly reduced the composite rate of cardiovascular

Read the full 605 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers